MIB1 labeling index as an indicator of chemoresponse in carcinoma of the breast

Applied Immunohistochemistry and Molecular Morphology

Volumn 12, Issue 4, 2004, Pages 290-295

  Sharma, Suash ^a   Saboorian, M Hossein ^a   Frawley, William H ^b   Frenkel, Eugene P ^b   Haley, Barbara B ^b   Ashfaq, Raheela ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Breast; Carcinoma; Chemotherapy; Immunohistochemistry; MIB1

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ARTICLE; BREAST BIOPSY; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG RESPONSE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGING SYSTEM; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MAJOR CLINICAL STUDY; ONCOGENE NEU; PLOIDY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL;

EID: 10044292936     PISSN: 15412016     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129039-200412000-00002     Document Type: Article

References (17)

1. Railo M, Nordling S, von Boguslawsky K, et al. Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer. 1993;68:579-583.
2. Veronese SM, Gambacorta M, Gottardi O, et al. Proliferation index as a prognostic marker in breast cancer. Cancer. 1993;71:3926-3931.
3. Howat JMT, Harris M, Swindell R, et al. The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast. Br J Cancer. 1985;51:263-270.
4. Daidone MG, Silvestrini R, Luisi A, et al. Changes in biological markers after primary chemotherapy for breast cancers. Int J Cancer. 1995;61:301-305.
5. Colleoni E, Orvieto E, Orlando L, et al. Prediction of response to primary chemotherapy for operable breast cancer. Eur J Cancer. 1999;35:574-579.
6. Railo M, Nordling S, Krogerus L, et al. Preoperative assessment of proliferative activity and hormone receptor status in carcinoma of the breast. Diag Cytopathol. 1996;15:205-210.
7. Ostrowski ML, Pindur J, Laucirica R, et al. Proliferative activity in invasive breast carcinoma: proliferative activity in invasive breast carcinoma. Acta Cytol. 2001;45:965-972.
8. Frierson HF Jr, Wolber RA, Berean KW, et al. Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol. 1995;103:195-198.
9. Keshgegian AA, Cnaan A. Proliferation markers in breast carcinoma: mitotic figure count, S-phase fraction, proliferating nuclear antigen, Ki-67, and MIB-1. Am J Clin Pathol. 1995;104:42-49.
10. Skoog L, Rutqvist LE, Wilking N. Analysis of hormone receptors and proliferation fraction in fine needle aspirates from primary breast carcinomas during chemotherapy or tamoxifen therapy. Acta Oncol. 1992;31:139-141.
11. Gonzalez-Vela MC, Garijo MF, Fernandez F, et al. MIB1 proliferation index in breast infiltrating carcinoma: comparison with other proliferative markers and association with new biological prognostic factors. Histol Histopathol. 2001;16:399-406.
12. Skalova A, Michal M. Importance of determination of proliferation markers and hormone receptors in breast carcinoma. Cas Lek Cesk. 1997;136:473-478.
13. Pinder SE, Wencyk P, Sibbering DM, et al. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer. 1995;71:146-149.
14. Puglisi F, Scalone S, Bazzocchi M, et al. Image-guided core breast biopsy: a suitable method for preoperative biological characterization of small (pT1) breast carcinomas. Cancer Lett. 1998;133:223-229.
15. Mauriac L, MacGrogan G, Avril A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol. 1999;10:47-52.
16. Amadori D, Volpi A, Maltoni R, et al. Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: a prospective study. Breast Cancer Res Treat. 1997;43:7-14.
17. Daidone MG, Silvestrini R, Valentinis B, et al. Changes in cell kinetics induced by primary chemotherapy in breast cancer. Int J Cancer. 1991;47:380-383.